Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry Klein

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor growth in xenograft models of solid tumors, and can induce significant tumor regression in some models. The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC. Methods: This Phase 2 multi-center study was designed to evaluate the efficacy, safety, and tolerability of mapatumumab in patients with advanced non-small cell lung cancer (NSCLC) previously treated with at least 1 platinum-based regimen. Each patient was to receive mapatumumab at a dose of 10 mg/kg administered intravenously (IV) every 21 days in absence of disease progression. Results: A total of 32 patients with relapsed or refractory Stage IIIB or IV or recurrent NSCLC were enrolled. Patients had received a median of 3 previous therapeutic regimens (range 1-7). Mapatumumab was well tolerated by the patients in this study with no discontinuations due to adverse events. The most common adverse events reported, regardless of relationship, were fatigue, cough, nausea, dyspnea, constipation, and vomiting. Laboratory analyses revealed no appreciable evidence of hepatic or renal toxicity among the study patients. No patients developed anti-mapatumumab antibodies. The plasma mapatumumab concentrations observed in this study were consistent with the predicted exposures, based on Phase 1 pharmacokinetic results. None of the 32 treated patients showed a response according to the RECIST criteria. Nine patients (29%) had stable disease (SD). Conclusion: In a group of heavily pretreated NSCLC patients, no objective single agent activity of mapatumumab was demonstrated, but the drug was safe and well tolerated. Based on this favorable safety profile, and preclinical evidence of potential synergy in combination with agents commonly used to treat NSCLC, future evaluation of mapatumumab in combination with chemotherapy is warranted.

Original languageEnglish (US)
Pages (from-to)82-90
Number of pages9
JournalLung Cancer
Volume61
Issue number1
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
Non-Small Cell Lung Carcinoma
Monoclonal Antibodies
Neoplasms
mapatumumab
Safety
Cell Line
Constipation
Combination Drug Therapy
Platinum
Cough
Heterografts
Dyspnea
Nausea
Vomiting
Fatigue
Disease Progression
Anti-Idiotypic Antibodies
Cell Survival
Cell Death

Keywords

  • HGS-ETR1
  • Mapatumumab
  • NSCLC
  • Phase 2
  • TRAIL-R1

ASJC Scopus subject areas

  • Oncology

Cite this

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. / Greco, F. Anthony; Bonomi, Philip; Crawford, Jeffrey; Kelly, Karen; Oh, Yun; Halpern, Wendy; Lo, Larry; Gallant, Gilles; Klein, Jerry.

In: Lung Cancer, Vol. 61, No. 1, 07.2008, p. 82-90.

Research output: Contribution to journalArticle

Greco, F. Anthony ; Bonomi, Philip ; Crawford, Jeffrey ; Kelly, Karen ; Oh, Yun ; Halpern, Wendy ; Lo, Larry ; Gallant, Gilles ; Klein, Jerry. / Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. In: Lung Cancer. 2008 ; Vol. 61, No. 1. pp. 82-90.
@article{e1c113a33ef94be3ad29f4b3b95565dc,
title = "Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer",
abstract = "Background: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor growth in xenograft models of solid tumors, and can induce significant tumor regression in some models. The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC. Methods: This Phase 2 multi-center study was designed to evaluate the efficacy, safety, and tolerability of mapatumumab in patients with advanced non-small cell lung cancer (NSCLC) previously treated with at least 1 platinum-based regimen. Each patient was to receive mapatumumab at a dose of 10 mg/kg administered intravenously (IV) every 21 days in absence of disease progression. Results: A total of 32 patients with relapsed or refractory Stage IIIB or IV or recurrent NSCLC were enrolled. Patients had received a median of 3 previous therapeutic regimens (range 1-7). Mapatumumab was well tolerated by the patients in this study with no discontinuations due to adverse events. The most common adverse events reported, regardless of relationship, were fatigue, cough, nausea, dyspnea, constipation, and vomiting. Laboratory analyses revealed no appreciable evidence of hepatic or renal toxicity among the study patients. No patients developed anti-mapatumumab antibodies. The plasma mapatumumab concentrations observed in this study were consistent with the predicted exposures, based on Phase 1 pharmacokinetic results. None of the 32 treated patients showed a response according to the RECIST criteria. Nine patients (29{\%}) had stable disease (SD). Conclusion: In a group of heavily pretreated NSCLC patients, no objective single agent activity of mapatumumab was demonstrated, but the drug was safe and well tolerated. Based on this favorable safety profile, and preclinical evidence of potential synergy in combination with agents commonly used to treat NSCLC, future evaluation of mapatumumab in combination with chemotherapy is warranted.",
keywords = "HGS-ETR1, Mapatumumab, NSCLC, Phase 2, TRAIL-R1",
author = "Greco, {F. Anthony} and Philip Bonomi and Jeffrey Crawford and Karen Kelly and Yun Oh and Wendy Halpern and Larry Lo and Gilles Gallant and Jerry Klein",
year = "2008",
month = "7",
doi = "10.1016/j.lungcan.2007.12.011",
language = "English (US)",
volume = "61",
pages = "82--90",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

AU - Greco, F. Anthony

AU - Bonomi, Philip

AU - Crawford, Jeffrey

AU - Kelly, Karen

AU - Oh, Yun

AU - Halpern, Wendy

AU - Lo, Larry

AU - Gallant, Gilles

AU - Klein, Jerry

PY - 2008/7

Y1 - 2008/7

N2 - Background: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor growth in xenograft models of solid tumors, and can induce significant tumor regression in some models. The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC. Methods: This Phase 2 multi-center study was designed to evaluate the efficacy, safety, and tolerability of mapatumumab in patients with advanced non-small cell lung cancer (NSCLC) previously treated with at least 1 platinum-based regimen. Each patient was to receive mapatumumab at a dose of 10 mg/kg administered intravenously (IV) every 21 days in absence of disease progression. Results: A total of 32 patients with relapsed or refractory Stage IIIB or IV or recurrent NSCLC were enrolled. Patients had received a median of 3 previous therapeutic regimens (range 1-7). Mapatumumab was well tolerated by the patients in this study with no discontinuations due to adverse events. The most common adverse events reported, regardless of relationship, were fatigue, cough, nausea, dyspnea, constipation, and vomiting. Laboratory analyses revealed no appreciable evidence of hepatic or renal toxicity among the study patients. No patients developed anti-mapatumumab antibodies. The plasma mapatumumab concentrations observed in this study were consistent with the predicted exposures, based on Phase 1 pharmacokinetic results. None of the 32 treated patients showed a response according to the RECIST criteria. Nine patients (29%) had stable disease (SD). Conclusion: In a group of heavily pretreated NSCLC patients, no objective single agent activity of mapatumumab was demonstrated, but the drug was safe and well tolerated. Based on this favorable safety profile, and preclinical evidence of potential synergy in combination with agents commonly used to treat NSCLC, future evaluation of mapatumumab in combination with chemotherapy is warranted.

AB - Background: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor growth in xenograft models of solid tumors, and can induce significant tumor regression in some models. The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC. Methods: This Phase 2 multi-center study was designed to evaluate the efficacy, safety, and tolerability of mapatumumab in patients with advanced non-small cell lung cancer (NSCLC) previously treated with at least 1 platinum-based regimen. Each patient was to receive mapatumumab at a dose of 10 mg/kg administered intravenously (IV) every 21 days in absence of disease progression. Results: A total of 32 patients with relapsed or refractory Stage IIIB or IV or recurrent NSCLC were enrolled. Patients had received a median of 3 previous therapeutic regimens (range 1-7). Mapatumumab was well tolerated by the patients in this study with no discontinuations due to adverse events. The most common adverse events reported, regardless of relationship, were fatigue, cough, nausea, dyspnea, constipation, and vomiting. Laboratory analyses revealed no appreciable evidence of hepatic or renal toxicity among the study patients. No patients developed anti-mapatumumab antibodies. The plasma mapatumumab concentrations observed in this study were consistent with the predicted exposures, based on Phase 1 pharmacokinetic results. None of the 32 treated patients showed a response according to the RECIST criteria. Nine patients (29%) had stable disease (SD). Conclusion: In a group of heavily pretreated NSCLC patients, no objective single agent activity of mapatumumab was demonstrated, but the drug was safe and well tolerated. Based on this favorable safety profile, and preclinical evidence of potential synergy in combination with agents commonly used to treat NSCLC, future evaluation of mapatumumab in combination with chemotherapy is warranted.

KW - HGS-ETR1

KW - Mapatumumab

KW - NSCLC

KW - Phase 2

KW - TRAIL-R1

UR - http://www.scopus.com/inward/record.url?scp=45649084324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45649084324&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.12.011

DO - 10.1016/j.lungcan.2007.12.011

M3 - Article

VL - 61

SP - 82

EP - 90

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -